$33.37
+0.23(0.69%)
Mkt Cap $3.6B
$11.42
$33.33
52-Week Range
At A Glance
1
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.
2
Most recently: and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange (2026-02-26).
$3.6B
Market Cap
—
Revenue
-$175M
Net Income
Employees117
Fundamentals
How The Business Makes Money
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001710072
ISINUS28036F1057
CUSIP28036F105
Phone303 735 8373
Address3415 Colorado Avenue, Boulder, CO, 80303, US
SEC EDGAR